- Home
- ARQT vs ARCB Comparison
ARQT vs ARCB Comparison
Compare ARQT & ARCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARQT | ARCB |
|---|---|---|
| Founded | 2016 | 1923 |
| Country | United States | United States |
| Employees | N/A | 14000 |
| Industry | Biotechnology: Pharmaceutical Preparations | Trucking Freight/Courier Services |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 2.7B |
| IPO Year | 2020 | 1994 |
Fundamental Metrics
Financial Performance| Metric | ARQT | ARCB |
|---|---|---|
| Price | $20.44 | $124.57 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 12 |
| Target Price | $34.00 | ★ $122.75 |
| AVG Volume (30 Days) | ★ 1.8M | 309.2K |
| Earning Date | 05-06-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 0.38% |
| EPS Growth | ★ 88.79 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $376,072,000.00 | ★ $1,657,864,000.00 |
| Revenue This Year | $34.85 | $7.00 |
| Revenue Next Year | $29.39 | $5.80 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 91.34 | 12.56 |
| 52 Week Low | $12.72 | $59.43 |
| 52 Week High | $31.77 | $135.10 |
Technical Indicators
Market Signals| Indicator | ARQT | ARCB |
|---|---|---|
| Relative Strength Index (RSI) | 39.63 | 58.89 |
| Support Level | $19.60 | $115.28 |
| Resistance Level | $24.56 | $135.10 |
| Average True Range (ATR) | 1.27 | 4.90 |
| MACD | -0.20 | -0.56 |
| Stochastic Oscillator | 23.32 | 73.47 |
Price Performance
Historical ComparisonAbout ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.
About ARCB ArcBest Corporation
ArcBest Corp is an integrated logistics company that leverages technology and a full suite of shipping and logistics solutions to meet customers' supply chain needs. The company has two reportable operating segments: Asset-Based, which generates maximum revenue, and Asset-Light. The Asset-Based segment's operations include national, inter-regional, and regional transportation of general commodities through standard, expedited, and guaranteed less-than-truckload services. The Asset-Light segment represents the company's offerings in ground expedite, intermodal, household goods moving, managed transportation, warehousing and distribution, and international freight transportation for air, ocean, and ground.